Researchers across the world are using QIAGEN Digital Insights solutions to accelerate their work in a variety of applications
Powerful insights help innovate, integrate and translate scientific results into impactful discoveries. Many noteworthy papers cite QIAGEN Digital Insights solutions and demonstrate how our tools help drive research insights and discoveries. These papers use QIAGEN Ingenuity Pathway Analysis (IPA), QIAGEN CLC and/or QIAGEN OmicSoft to help drive success. The QIAGEN Digital Insights portfolio encompasses a comprehensive, easy-to-use toolbox that ensures continuity in NGS workflow. Here, we have curated a selection of just a few recent papers to offer a sense of the diversity of the research for which QIAGEN Digital Insights solutions makes a difference.
First author: Bo Shen
Virologists at Wenzhou Medical University use machine learning to help identify potentially severe COVID19 cases. Learn how they use QIAGEN IPA to understand proteomic and metabolomic changes to identify blood markers that could predict COVID-19 severity. Read their full paper here.
First author: Joseph Collin
Potential SARS-CoV-2 transmission through the eyes? Discover this fascinating research by Dr. J. Collin and colleagues at Newcastle University, who are studying a possible ocular route of transmission for SARS-CoV-2. Learn how the team uses QIAGEN IPA’s Upstream Regulator Analysis to understand how the virus may exploit ACE2 and TMPRSS2 co-expression in the eyes to gain systemic entry. Read the full article here.
First Author: Mateusz Wietecha
Novel research by Dr. M. Wietecha and colleagues at ETH Zurich who study scar tissue formation during wound healing. Learn how the team uses QIAGEN CLC Genomics Workbench and QIAGEN IPA to understand how activin A affects the wound healing process and could be a key factor in wound fibrosis. Read their full paper here in Nature Communications.
First author: Mehdi Eshraghi
Parkinson’s researchers at the Scripps Research Institute investigate the role of RasGRP1 in causing L-DOPA–induced dyskinesia. Learn how the team uses QIAGEN IPA to understand the molecular mechanism of how this guanine nucleotide exchange factor contributes to this disease. Read their full paper here.
Conditional deletion of Nedd4-2 in lung epithelial cells causes progressive pulmonary fibrosis in adult mice
First author: Julia Duerr
Researchers at the University of Heidelberg use QIAGEN IPA to investigate the role of Nedd4-2 in progressive idiopathic pulmonary fibrosis. See how QIAGEN IPA helps the team identify processes and pathways affected by treatment with the anti-fibrotic drug pirfenidone in a Nedd4-2 conditional deletion mouse model. Read their full paper in Nature Communications.
First author: Rishi K. Gupta
Critical tuberculosis research by R. Gupta and colleagues from University College London who investigate transcriptional signatures to identify potential tuberculosis infection in patients. See how the team uses QIAGEN IPA to research blood transcriptional biomarkers that could be used to identify high-risk tuberculosis patients. Read the full paper from Lancet Respiratory Medicine.
First author: Jana Goebel
In honor of brain injury awareness month, we are highlighting fascinating research from the University of Cologne, Germany, where J. Gӧbel and colleagues look at the physical interaction between the endoplasmic reticulum and mitochondria and its role in promoting vascular remodeling in astrocytes. See how the team uses QIAGEN IPA to investigate this mitochondrial dynamic in brain injury wound healing. Read the full paper in Cell Metabolism.
First author: Pranabananda Dutta
Dutta and colleagues at Charles Drew University are studying the role of PARP1 in metastatic breast cancer. The team uses QIAGEN CLC Genomics Workbench and QIAGEN IPA to understand how PARP1 interacts with CCL2, a driver for invasiveness in breast cancer. Access their full article here.
First author: Omar Warsi
Discover fascinating research by Dr. Warsi and colleagues at Uppsala University, where they conferred a new function in bacteria by creating a chimeric fusion between phage DNA and a bacterial gene. The team used QIAGEN CLC Genomics Workbench to understand how the fusion of mobile genetic elements generates novel functions in bacteria. Read their full paper here.
First author: So Ra Kim
Discover exciting research by S. R. Kim and colleagues at Yonsei University who study the role of SGLT2 in modulating NLRP3 inflammasome activity in diabetic patients. They use the powerful QIAGEN CLC Genomics Workbench to investigate how SGLT2 inhibition helps reduce cardiovascular events. Read the full paper in Nature Communications here.
First author: Na Zhu
Exciting coronavirus research by N. Zhu and colleagues at The Chinese Center for Disease Control, who report how they identified the novel coronavirus responsible for COVID-19. Discover how the team uses QIAGEN CLC Genomics Workbench in the data analysis of next-generation sequencing of samples from pneumonia patients in Wuhan, China. Read their New England Journal of Medicine publication here.
First author: Takuro Horii
Discover this fantastic research by T. Horii and colleagues at Gunma University in Japan, where they are working on creating an epigenetic mouse disease model using targeted methylation of the genome. Learn how the team uses QIAGEN extraction kits and QIAGEN CLC Genomics Workbench to create a Silver-Russell syndrome animal model using targeted demethylation. Read the full paper here.
First author: Koichi Fujisawa
Researchers at Yamaguchi University are studying transcriptomic and metabolomic changes in hepatic stellate cells in spheroid culture to better understand liver fibrosis. Discover how they use QIAGEN OmicSoft Suite and QIAGEN IPA to identify key changes that deepen our understanding of liver fibrosis. Read the full paper here.
First author: Liana Basova
What’s the connection between drug use and certain viruses? Discover this fascinating research by Dr. L. Basova and colleagues at the San Diego Biomedical Research Institute, who investigate the effects of reward circuitry inhibiting the TAT protein in HIV patients using methamphetamines. See how the team uses QIAGEN OmicSoft ArrayStudio together with QIAGEN IPA to understand how TAT has an antagonizing effect on meth-induced transcriptional changes in a neuroHIV mouse model. Read the full paper in Viruses.
First author: Jim S. Qin
Cancer researchers at Juno Therapeutics investigate the effectiveness of a new anti-CD19 T-cell therapy. See how the team uses QIAGEN ArrayStudio to research a combination therapy of lisocabtagene maraleucel and ibrutinib or acalabrutinib in hopes to improve outcomes in CD19+ B-cell malignancies. Read the full paper here.
First author: Cristina A. Nadalutti
Researchers at the National Institute of Environmental Health Sciences (NIEHS) use QIAGEN OmicSoft Array Suite to study how increases in cellular formaldehyde cause mitochondrial dysfunction and DNA damage in cultured primary human fibroblasts. Read the full paper here.
To request information on the QIAGEN Digital Insight solutions, contact email@example.com.